Basic Information
RNALocate ID: | RLID:11001395 |
RNA Symbol: | hsa-miR-34a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-34a |
RNA ID: | miRBase:MIMAT0000255 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20976003 |
Tissue/Cell Line: | Breast cancer cell line (MCF-7) |
Method: | Microarray |
Description: | Because of the suggested roles of extracellular miRNAs in signaling and diagnosis, we investigated whether the intracellular and extracellular miRNA composition are the same. To answer this question, we performed microRNA microarray analyses of MCF7 cellular (c) and extracellular (x) RNAs (Figure 2A), and found that about 66% of the released miRNAs are at an abundance that closely reflects the cellular miRNA abundance (Figures 2B and 2C). This finding is in agreement with a model wherein most, but not all miRNAs are released passively by mass action. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001607 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001608 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001609 | Mitochondrion | Myotube | 27396686 |
RLID:01001610 | Mitochondrion | Skeletal muscle cells | 27563705 |
RLID:01001611 | Mitochondrion | Human umbilical vein endothelial cells | 30348904 |
RLID:01001612 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001613 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001614 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:11001396 | Exosome | Primary dendritic cells | 21505438 |
RLID:11001397 | Exosome | Breast milk | 22211110 |
RLID:11001398 | Exosome | Brain tissue | 23382797 |
RLID:11001399 | Exosome | Plasma | 23663360 |
RLID:11001400 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001401 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11001402 | Extracellular vesicle | Human mesenchymal stem cells | 25669974 |
RLID:11001403 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001404 | Microvesicle | Serum | 24797360 |
RLID-D:11000048 | Exosome | B lymphoblastoid cells | |
RLID-D:11000317 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-34a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-42622 |
MNDR | hsa-miR-34a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-42623 |
MNDR | hsa-miR-34a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-42624 |
MNDR | hsa-miR-34a-5p | Proneural subtype glioblastoma | MNDR-E-MI-42625 |
MNDR | hsa-miR-34a-5p | Glomerulosclerosis | MNDR-E-MI-42626 |
MNDR | hsa-miR-34a-5p | Oral squamous cell carcinoma | MNDR-E-MI-42627 |
MNDR | hsa-miR-34a-5p | Medulloblastoma | MNDR-E-MI-42628 |
MNDR | hsa-miR-34a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-42629 |
MNDR | hsa-miR-34a-5p | Lymphoma | MNDR-E-MI-42630 |
MNDR | hsa-miR-34a-5p | Lymphoma non-hodgkin | MNDR-E-MI-42631 |
MNDR | hsa-miR-34a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-42632 |
MNDR | hsa-miR-34a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-42633 |
MNDR | hsa-miR-34a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-42634 |
MNDR | hsa-miR-34a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-42635 |
MNDR | hsa-miR-34a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-42636 |
MNDR | hsa-miR-34a-5p | Triple negative breast cancer | MNDR-E-MI-42637 |
MNDR | hsa-miR-34a-5p | Neuroblastoma with 1p36 deletion | MNDR-E-MI-42638 |
MNDR | hsa-miR-34a-5p | Breast cancer luminal | MNDR-E-MI-42639 |
MNDR | hsa-miR-34a-5p | Anencephaly | MNDR-E-MI-42640 |
MNDR | hsa-miR-34a-5p | Niemann-pick disease type c | MNDR-E-MI-42641 |
MNDR | hsa-miR-34a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-42642 |
MNDR | hsa-miR-34a-5p | Hearing loss central | MNDR-E-MI-42643 |
MNDR | hsa-miR-34a-5p | Sensorineural hearing loss | MNDR-E-MI-42644 |
MNDR | hsa-miR-34a-5p | Dermatomyositis | MNDR-E-MI-42645 |
MNDR | hsa-miR-34a-5p | Prostate cancer | MNDR-E-MI-42646 |
MNDR | hsa-miR-34a-5p | Chronic lymphocytic leukemia | MNDR-E-MI-42647 |
MNDR | hsa-miR-34a-5p | Gastric cancer | MNDR-E-MI-42648 |
MNDR | hsa-miR-34a-5p | Gastric lymphoma | MNDR-E-MI-42649 |
MNDR | hsa-miR-34a-5p | Alzheimer disease | MNDR-E-MI-42650 |
MNDR | hsa-miR-34a-5p | Intracranial aneurysm | MNDR-E-MI-42651 |
MNDR | hsa-miR-34a-5p | Bladder cancer | MNDR-E-MI-42652 |
MNDR | hsa-miR-34a-5p | Sarcoidosis | MNDR-E-MI-42653 |
MNDR | hsa-miR-34a-5p | Dysautonomia familial | MNDR-E-MI-42654 |
MNDR | hsa-miR-34a-5p | Myotonic dystrophy | MNDR-E-MI-42655 |
MNDR | hsa-miR-34a-5p | Muscular dystrophy duchenne | MNDR-E-MI-42656 |
MNDR | hsa-miR-34a-5p | Facioscapulohumeral muscular dystrophy | MNDR-E-MI-42657 |
MNDR | hsa-miR-34a-5p | Prader-willi syndrome | MNDR-E-MI-42658 |
MNDR | hsa-miR-34a-5p | Leukemia | MNDR-E-MI-42659 |
MNDR | hsa-miR-34a-5p | Cardiovascular disease | MNDR-E-MI-42660 |
MNDR | hsa-miR-34a-5p | Uterine fibroid | MNDR-E-MI-42661 |
MNDR | hsa-miR-34a-5p | Lung cancer | MNDR-E-MI-42662 |
MNDR | hsa-miR-34a-5p | Tuberous sclerosis | MNDR-E-MI-42663 |
MNDR | hsa-miR-34a-5p | Parkinson disease | MNDR-E-MI-42664 |
MNDR | hsa-miR-34a-5p | Niemann-pick disease | MNDR-E-MI-42665 |
MNDR | hsa-miR-34a-5p | Primary pulmonary hypertension | MNDR-E-MI-42666 |
MNDR | hsa-miR-34a-5p | Major depressive disorder | MNDR-E-MI-42667 |
MNDR | hsa-miR-34a-5p | Basal-like breast cancer | MNDR-E-MI-42668 |
MNDR | hsa-miR-34a-5p | Cancer | MNDR-E-MI-42669 |
MNDR | hsa-miR-34a-5p | Squamous cell carcinoma | MNDR-E-MI-42670 |
MNDR | hsa-miR-34a-5p | Pituitary neoplasms | MNDR-E-MI-42671 |
MNDR | hsa-miR-34a-5p | Pancreatic cancer | MNDR-E-MI-42672 |
MNDR | hsa-miR-34a-5p | Melanoma | MNDR-E-MI-42673 |
MNDR | hsa-miR-34a-5p | Lesch-nyhan syndrome | MNDR-E-MI-42674 |
MNDR | hsa-miR-34a-5p | Rectum adenocarcinoma | MNDR-E-MI-42675 |
MNDR | hsa-miR-34a-5p | Nephroblastoma | MNDR-E-MI-42676 |
MNDR | hsa-miR-34a-5p | Colon cancer | MNDR-E-MI-42677 |
MNDR | hsa-miR-34a-5p | Colon adenocarcinoma | MNDR-E-MI-42678 |
MNDR | hsa-miR-34a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-42679 |
MNDR | hsa-miR-34a-5p | Ovarian cancer | MNDR-E-MI-42680 |
MNDR | hsa-miR-34a-5p | Laryngeal squamous cell carcinoma | MNDR-E-MI-42681 |
MNDR | hsa-miR-34a-5p | Glioblastoma | MNDR-E-MI-42682 |
MNDR | hsa-miR-34a-5p | Astrocytoma | MNDR-E-MI-42683 |
MNDR | hsa-miR-34a-5p | Glioma | MNDR-E-MI-42684 |
MNDR | hsa-miR-34a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-42685 |
MNDR | hsa-miR-34a-5p | Chordoma | MNDR-E-MI-42686 |
MNDR | hsa-miR-34a-5p | Bipolar disorder | MNDR-E-MI-42687 |
MNDR | hsa-miR-34a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-42688 |
MNDR | hsa-miR-34a-5p | Osteosarcoma | MNDR-E-MI-42689 |
MNDR | hsa-miR-34a-5p | Ewing sarcoma | MNDR-E-MI-42690 |
MNDR | hsa-miR-34a-5p | Liposarcoma | MNDR-E-MI-42691 |
MNDR | hsa-miR-34a-5p | Inclusion body myositis | MNDR-E-MI-42692 |
MNDR | hsa-miR-34a-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-42693 |
MNDR | hsa-miR-34a-5p | Meningioma | MNDR-E-MI-42694 |
MNDR | hsa-miR-34a-5p | Central nervous system cancer | MNDR-E-MI-42695 |
MNDR | hsa-miR-34a-5p | Uterine cancer | MNDR-E-MI-42696 |
MNDR | hsa-miR-34a-5p | Cervical adenocarcinoma | MNDR-E-MI-42697 |
MNDR | hsa-miR-34a-5p | Gastric adenocarcinoma | MNDR-E-MI-42698 |
MNDR | hsa-miR-34a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-42699 |
MNDR | hsa-miR-34a-5p | Pulmonary fibrosis | MNDR-E-MI-42700 |
MNDR | hsa-miR-34a-5p | Pituitary adenoma | MNDR-E-MI-42701 |
MNDR | hsa-miR-34a-5p | Lung squamous cell carcinoma | MNDR-E-MI-42702 |
MNDR | hsa-miR-34a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-42703 |
MNDR | hsa-miR-34a-5p | Lung adenocarcinoma | MNDR-E-MI-42704 |
MNDR | hsa-miR-34a-5p | Thyroid carcinoma | MNDR-E-MI-42705 |
MNDR | hsa-miR-34a-5p | Papillary thyroid carcinoma | MNDR-E-MI-42706 |
MNDR | hsa-miR-34a-5p | Ovarian carcinoma | MNDR-E-MI-42707 |
MNDR | hsa-miR-34a-5p | Invasive urothelial bladder carcinoma | MNDR-E-MI-42708 |
MNDR | hsa-miR-34a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-42709 |
MNDR | hsa-miR-34a-5p | Brain stem cancer | MNDR-E-MI-42710 |
MNDR | hsa-miR-34a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-42711 |
MNDR | hsa-miR-34a-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-42712 |
MNDR | hsa-miR-34a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-42713 |
MNDR | hsa-miR-34a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-42714 |
MNDR | hsa-miR-34a-5p | Cholangiocarcinoma | MNDR-E-MI-42715 |
MNDR | hsa-miR-34a-5p | Oncocytoma | MNDR-E-MI-42716 |
MNDR | hsa-miR-34a-5p | Lung small cell carcinoma | MNDR-E-MI-42717 |
MNDR | hsa-miR-34a-5p | Schizophrenia | MNDR-E-MI-42718 |
MNDR | hsa-miR-34a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-42719 |
MNDR | hsa-miR-34a-5p | Myocardial infarction | MNDR-E-MI-42720 |
MNDR | hsa-miR-34a-5p | Malignant peripheral nerve sheath tumor | MNDR-E-MI-42721 |
MNDR | hsa-miR-34a-5p | Heart failure | MNDR-E-MI-42722 |
MNDR | hsa-miR-34a-5p | Uveal melanoma | MNDR-E-MI-42723 |
MNDR | hsa-miR-34a-5p | HBV+ hepatocellular carcinoma | MNDR-E-MI-42724 |
MNDR | hsa-miR-34a-5p | Embryonal cancer | MNDR-E-MI-42725 |
MNDR | hsa-miR-34a-5p | B-cell lymphoma | MNDR-E-MI-42726 |
MNDR | hsa-miR-34a-5p | T-cell leukemia | MNDR-E-MI-42727 |
MNDR | hsa-miR-34a-5p | Retinoblastoma | MNDR-E-MI-42728 |
MNDR | hsa-miR-34a-5p | Neuroblastoma | MNDR-E-MI-42729 |
MNDR | hsa-miR-34a-5p | Hodgkin disease | MNDR-E-MI-42730 |
MNDR | hsa-miR-34a-5p | Burkitt lymphoma | MNDR-E-MI-42731 |
MNDR | hsa-miR-34a-5p | Mouth neoplasms | MNDR-E-MI-42732 |
MNDR | hsa-miR-34a-5p | Tonsil cancer | MNDR-E-MI-42733 |
MNDR | hsa-miR-34a-5p | Skin cutaneous melanoma | MNDR-E-MI-42734 |
MNDR | hsa-miR-34a-5p | Skin melanoma | MNDR-E-MI-42735 |
MNDR | hsa-miR-34a-5p | Acute myelocytic leukemia | MNDR-E-MI-42736 |
MNDR | hsa-miR-34a-5p | Colorectal cancer | MNDR-E-MI-42737 |
MNDR | hsa-miR-34a-5p | Nasopharynx carcinoma | MNDR-E-MI-42738 |
MNDR | hsa-miR-34a-5p | Acute lymphocytic leukemia | MNDR-E-MI-42739 |
MNDR | hsa-miR-34a-5p | Esophageal squamous cancer | MNDR-E-MI-42740 |
MNDR | hsa-miR-34a-5p | Ependymoma | MNDR-E-MI-42741 |
MNDR | hsa-miR-34a-5p | Nasopharyngeal cancer | MNDR-E-MI-42742 |
MNDR | hsa-miR-34a-5p | Prostatic neoplasms | MNDR-E-MI-42743 |
MNDR | hsa-miR-34a-5p | Polymyositis | MNDR-E-MI-42744 |
MNDR | hsa-miR-34a-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-42745 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABLIM1 | Homo sapiens | RR00027318 |
TOP